Mitapivat

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

6 competitors in Sickle Cell Disease

Drug Information

Target Indication

Sickle Cell Disease

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA11/9/2022

Pyrukynd

Pyrukynd is indicated for the treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (see section 4.4).

Orphan

Drug Science

Mechanism of action & safety profile

Developer

AGIO

Agios Pharmaceuticals, Inc.

Related Pipeline

Pyruvate Kinase Deficiency

Myelodysplastic Syndromes

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts